Components of the metabolic syndrome in long-term survivors of testicular cancer
| Autor: | Sophie D. Fosså, Tom Wilsgaard, Nina Aass, Hegesa S. Haugnes, Johan Svartberg, O. Klepp, Erik Wist, Olav Dahl, Roy M. Bremnes |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Adolescent medicine.medical_treatment Testicular Neoplasms Risk Factors Internal medicine medicine Humans Survivors National Cholesterol Education Program Testicular cancer Aged Metabolic Syndrome Chemotherapy business.industry Case-control study Hematology Odds ratio Middle Aged medicine.disease Combined Modality Therapy Chemotherapy regimen Surgery Oncology Case-Control Studies Population study Metabolic syndrome business Follow-Up Studies |
| Zdroj: | Annals of Oncology. 18:241-248 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdl372 |
| Popis: | Background: A possible explanation of the excess cardiovascular risk in testicular cancer (TC) survivors is development of metabolic syndrome. The association between metabolic syndrome and TC treatment is examined in long-term survivors. Patients and methods: In a national follow-up study (1998–2002), 1463 TC survivors (diagnosed 1980–1994) participated. Patients >60 years were excluded in the present study, leaving 1135 patients eligible. The patients were divided in four treatment groups: surgery (n = 225); radiotherapy (n = 446) and two chemotherapy groups: cumulative cisplatin dose (Cis) ≤850 mg (n = 376) and Cis >850 mg (n = 88). A control group consisted of 1150 men from the Tromso Population Study. Metabolic syndrome was defined according to a modified National Cholesterol Education Program definition. Results: Both chemotherapy groups had increased odds for metabolic syndrome compared with the surgery group, highest for the Cis >850 group [odds ratio (OR) 2.8, 95% confidence interval (CI) 1.6–4.7]. Also, the Cis >850 group had increased odds (OR 2.1, 95% CI 1.3–3.4) for metabolic syndrome compared with the control group. The association between metabolic syndrome and the Cis >850 group was strengthened after adjusting for testosterone, smoking, physical activity, education and family status. Conclusion: TC survivors treated with cisplatin-based chemotherapy have an increased risk of developing metabolic syndrome compared with patients treated with other modalities or with controls. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|